IC-ONC – Immuno-Oncology TeleECHO Session: Bladder Cancer
Tuesday, June 25, 2019
12:00 – 1:00PM ET
Please note this TeleECHO program is 12:00PM Eastern, 11:00AM, Central, 10:00AM Mountain and 9:00AM Pacific.
I. Cancer Cells, the Tumor Microenvironment and the Immune System
a. T-cell activation, proliferation, and regulation
b. Tumor immune evasion and tolerance
c. Detection and destruction of cancer cells by the immune system
II. Checkpoint Inhibitors
a. Function of CTLA-4, PD-1 and PD-L1 in T-cell regulation
b. Mechanism of action of immune checkpoint inhibitors
III. Clinical Evidence Supporting the Use of Checkpoint Inhibitors in the Treatment of Cancer
a. Rationale for anti-CTLA-4 and anti-PD-1 combination therapies
b. Evidence from clinical trials for bladder cancer
c. Identifying patients who would benefit from checkpoint inhibitors using biomarkers
IV. Immune-Related Adverse Events (irAEs)
a. Description of irAEs associated with checkpoint inhibitors
b. 2D Video Theme: irAEs
c. Monitoring and management of irAEs
V. Cancer Case Studies (Bladder Cancer)
a. Combining and sequencing immunotherapies
b. Recognizing and managing irAEs
c. Monitoring therapeutic responses
VII. Questions and Answers
Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.
The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.
Arjun Balar, MD
Associate Professor of Medicine
Director—Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU – Langone Health
New York, NY
After completing the CME activity, learners should be better able to:
- Assess the process by which tumor cells evade immune system detection and the mechanism of action of CTLA-4 and PD-1/PD-L1 inhibitors
- Analyze clinical data to identify candidates for immunotherapy based on tumor biomarkers and patient characteristics and develop/implement treatment plans that appropriately sequence and combine immunotherapies
- Examine clinical evidence supporting the use of CTLA-4 and PD-1/PD-L1 inhibitors in those three histologies and compare the efficacy of monotherapy versus combination therapy with checkpoint blockade and/or chemotherapy
- Identify immune-related adverse events (irAEs) associated with checkpoint inhibitors and discuss how to optimally manage them
This initiative is designed to meet the educational needs of oncologists, oncology pharmacists,
oncology nurses and other healthcare professionals interested in the use of immunotherapy for
the management of patients with cancer.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 Credit(s)TM.
Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSING CREDIT INFORMATION
This program would be beneficial for nurses involved in the care of patients with Bladder Cancer.
1.0 ANCC Contact Hour(s)
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact: Med Learning Group at email@example.com.
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.